| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T646 |
0-221 |
Sentence |
denotes |
There are many factors to consider when repurposing approved drugs for a new indication, and identification of key protein targets that are potently inhibited offers an attractive option for a new therapeutic application. |
| T647 |
222-477 |
Sentence |
denotes |
The urgency of need and constraints of time, however, which come with developing effective therapeutic approaches during a pandemic crisis can make it challenging to conduct well-controlled studies with data that definitively attribute efficacy to a drug. |
| T648 |
478-662 |
Sentence |
denotes |
Numerous agents, which show promise based on preclinical studies and anecdotal data, are presently under clinical investigation as single agents or in combination with other therapies. |
| T649 |
663-914 |
Sentence |
denotes |
Several kinase inhibitors are under clinical investigation for COVID-19 that target key virus-associated proteins as well as proteins that play a role in development of symptoms associated with COVID-19, including pneumonia, fibrosis and inflammation. |
| T650 |
915-1012 |
Sentence |
denotes |
For optimal drug repurposing, the pharmacokinetics of agents need to be taken into consideration. |
| T651 |
1013-1248 |
Sentence |
denotes |
For instance, drugs that require long-term dosing to achieve optimal drug concentrations and anti-inflammatory effects, may not easily treat the symptoms of COVID-19 due to the immediacy of treatment requirement for afflicted patients. |
| T652 |
1249-1410 |
Sentence |
denotes |
Similarly, adverse effects associated with some kinase inhibitors also need to be considered and may present a challenge for treatment of some COVID-19 patients. |
| T653 |
1411-1463 |
Sentence |
denotes |
However, short-term dosing may minimize these risks. |
